Medtronic received information via literature regarding a comparison of the outcomes in patients with degenerated stentless or stented aortic bioprosthetic valves who underwent valve-in-valve transcatheter aortic valve replacement (tavr).All data were collected from multiple centers between 2007 and 2016.The study population included 1,598 (predominantly male; mean age 76 years), 377 of which were previously implanted with medtronic mosaic (161), hancock (138), freestyle (75), and ats 3f (3) bioprosthetic valves; 804 were implanted valve-in-valve with medtronic corevalve (528), evolut r (270), and melody (6) transcatheter valves.No serial numbers were provided.Among all corevalve and evolut r patients, 38 deaths occurred within 30 days post implant.No other details were reported.Based on the available information, medtronic product was not directly associated with the deaths.Among the entire study cohort, 74 patients died within 30 days post-tavr implant and 211 died within 1-year post-tavr implant, respectively.Based on the available information, medtronic product was not directly associated with the deaths.Among all mosaic, hancock, freestyle, and ats 3f patients, adverse events included: valve-in-valve implantation due to aortic regurgitation (mild-moderate-severe), aortic stenosis, or a combination of both, and high peak/mean aortic gradients.Based on the available information, medtronic product may have been associated with the adverse events.Among all corevalve, evolut r, and melody patients, adverse events included: new permanent pacemaker implantation, major stroke, second transcatheter valve required, coronary obstruction, mild-moderate-severe aortic regurgitation/paravalvular leak, prosthesis-patient mismatch, valve malposition (low/high implant), valve migration during index procedure (1 reported corevalve case), major bleeding, major vascular complications, decreased left ventricular ejection fraction, and elevated peak/mean aortic gradients.Based on the available information, medtronic product may have been associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
|